`
`
`
`ABILIFY® (aripiprazole)
`ABILIFY® (aripiprazole) Tablets
`ABILIFY® DISCMELT™ (aripiprazole) Orally Disintegrating Tablets
`ABILIFY® (aripiprazole) Oral Solution
`ABILIFY® (aripiprazole) Injection FOR INTRAMUSCULAR USE ONLY
`
`
`WARNING
`
`Increased Mortality in Elderly Patients with Dementia-Related
`Psychosis
`
`Elderly patients with dementia-related psychosis treated with atypical antipsychotic
`drugs are at an increased risk of death compared to placebo. Analyses of seventeen
`placebo-controlled trials (modal duration of 10 weeks) in these patients revealed a
`risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in
`placebo-treated patients. Over the course of a typical 10-week controlled trial, the
`rate of death in drug-treated patients was about 4.5%, compared to a rate of about
`2.6% in the placebo group. Although the causes of death were varied, most of the
`deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or
`infectious (eg, pneumonia) in nature. ABILIFY is not approved for the treatment of
`patients with dementia-related psychosis.
`
`DESCRIPTION
`
`Aripiprazole is a psychotropic drug that is available as ABILIFY® (aripiprazole) tablets,
`tablets, ABILIFY®
`ABILIFY® DISCMELT™ (aripiprazole) orally disintegrating
`(aripiprazole) oral solution, and ABILIFY® (aripiprazole) injection, a solution for
`intramuscular
`injection.
`Aripiprazole
`is
`7-[4-[4-(2,3-dichlorophenyl)-1-
`piperazinyl]butoxy]-3,4-dihydrocarbostyril. The empirical formula is C23H27Cl2N3O2 and
`its molecular weight is 448.39.
`
`1
`
`2
`
`3
`4
`5
`6
`7
`
`8
`
`9
`10
`
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`
`21
`
`22
`
`23
`
`24
`25
`26
`27
`
`1 of 53
`
`Approved 1.0
`
`Item 2 current.pdf
`
`
`
`
`The chemical structure is:
`
`28
`
`Cl
`
`Cl
`
`O
`
`NH
`
`N
`
`N
`
`CH2CH2CH2CH2O
`
`
`
`ABILIFY tablets are available in 2-mg, 5-mg, 10-mg, 15-mg, 20-mg, and 30-mg
`strengths. Inactive ingredients include cornstarch, hydroxypropyl cellulose, lactose
`monohydrate, magnesium stearate, and microcrystalline cellulose. Colorants include
`ferric oxide (yellow or red) and FD&C Blue No. 2 Aluminum Lake.
`
`ABILIFY DISCMELT orally disintegrating tablets are available in 10-mg and 15-
`mg strengths. Inactive ingredients include acesulfame potassium, aspartame, calcium
`silicate, croscarmellose sodium, crospovidone, crème de vanilla (natural and artificial
`flavors), magnesium stearate, microcrystalline cellulose, silicon dioxide, tartaric acid, and
`xylitol. Colorants include ferric oxide (yellow or red) and FD&C Blue No. 2 Aluminum
`Lake.
`
`ABILIFY is also available as a 1-mg/mL oral solution. The inactive ingredients
`this solution
`include disodium edetate, fructose, glycerin, dl-lactic acid,
`for
`methylparaben, propylene glycol, propylparaben, sodium hydroxide, sucrose, and
`purified water. The oral solution is flavored with natural orange cream and other natural
`flavors.
`
`ABILIFY Injection is available in single-dose vials as a ready-to-use, 9.75 mg/1.3
`mL (7.5 mg/mL), clear, colorless, sterile, aqueous solution for intramuscular use only.
`Inactive ingredients for this solution include 150 mg/mL of sulfobutylether β-
`cyclodextrin (SBECD), tartaric acid, sodium hydroxide, and water for injection.
`
`CLINICAL PHARMACOLOGY
`
`Pharmacodynamics
`
`Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5-
`HT2A receptors (Ki values of 0.34, 0.8, 1.7, and 3.4 nM, respectively), moderate affinity
`2 of 53
`
`Approved 1.0
`
`Item 2 current.pdf
`
`29
`
`30
`31
`32
`33
`
`34
`35
`36
`37
`38
`39
`
`40
`41
`42
`43
`44
`
`45
`46
`47
`48
`
`49
`
`50
`
`51
`
`52
`
`
`
`
`for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha1-adrenergic and histamine H1
`receptors (Ki values of 44, 15, 39, 57, and 61 nM, respectively), and moderate affinity for
`the serotonin reuptake site (Ki=98 nM). Aripiprazole has no appreciable affinity for
`cholinergic muscarinic receptors (IC50>1000 nM). Aripiprazole functions as a partial
`agonist at the dopamine D2 and the serotonin 5-HT1A receptors, and as an antagonist at
`serotonin 5-HT2A receptor.
`
`The mechanism of action of aripiprazole, as with other drugs having efficacy in
`schizophrenia, bipolar disorder, and agitation associated with schizophrenia or bipolar
`disorder, is unknown. However, it has been proposed that the efficacy of aripiprazole is
`mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors
`and antagonist activity at 5-HT2A receptors. Actions at receptors other than D2, 5-HT1A,
`and 5-HT2A may explain some of the other clinical effects of aripiprazole, eg, the
`orthostatic hypotension observed with aripiprazole may be explained by its antagonist
`activity at adrenergic alpha1 receptors.
`
`Pharmacokinetics
`
`ABILIFY (aripiprazole) activity is presumably primarily due to the parent drug,
`aripiprazole, and to a lesser extent, to its major metabolite, dehydro-aripiprazole, which
`has been shown to have affinities for D2 receptors similar to the parent drug and
`represents 40% of the parent drug exposure in plasma. The mean elimination half-lives
`are about 75 hours and 94 hours for aripiprazole and dehydro-aripiprazole, respectively.
`Steady-state concentrations are attained within 14 days of dosing for both active moieties.
`Aripiprazole accumulation is predictable from single-dose pharmacokinetics. At steady
`state, the pharmacokinetics of aripiprazole are dose-proportional. Elimination of
`aripiprazole is mainly through hepatic metabolism involving two P450 isozymes,
`CYP2D6 and CYP3A4.
`
`Pharmacokinetic studies showed that ABILIFY DISCMELT orally disintegrating
`tablets are bioequivalent to ABILIFY tablets.
`
`53
`
`54
`
`55
`
`56
`
`57
`
`58
`
`59
`60
`61
`62
`
`63
`
`64
`65
`66
`
`67
`
`68
`69
`70
`71
`72
`73
`74
`75
`76
`77
`
`78
`79
`
`3 of 53
`
`Approved 1.0
`
`Item 2 current.pdf
`
`
`
`80
`
`81
`
`82
`
`83
`84
`85
`86
`87
`88
`
`89
`
`90
`91
`92
`93
`94
`95
`96
`97
`
`98
`
`99
`100
`101
`102
`103
`104
`
`105
`
`106
`107
`
`
`ORAL ADMINISTRATION
`
`Absorption
`
`Tablet
`
`Aripiprazole is well absorbed after administration of the tablet, with peak plasma
`concentrations occurring within 3 to 5 hours; the absolute oral bioavailability of the tablet
`formulation is 87%. ABILIFY can be administered with or without food. Administration
`of a 15-mg ABILIFY tablet with a standard high-fat meal did not significantly affect the
`Cmax or AUC of aripiprazole or its active metabolite, dehydro-aripiprazole, but delayed
`Tmax by 3 hours for aripiprazole and 12 hours for dehydro-aripiprazole.
`
`Oral Solution
`
`Aripiprazole is well absorbed when administered orally as the solution. At equivalent
`doses, the plasma concentrations of aripiprazole from the solution were higher than that
`from the tablet formulation. In a relative bioavailability study comparing the
`pharmacokinetics of 30 mg aripiprazole as the oral solution to 30-mg aripiprazole tablets
`in healthy subjects, the solution to tablet ratios of geometric mean Cmax and AUC values
`were 122% and 114%, respectively (see DOSAGE AND ADMINISTRATION). The
`single-dose pharmacokinetics of aripiprazole were linear and dose-proportional between
`the doses of 5 to 30 mg.
`
`Distribution
`
`intravenous
`The steady-state volume of distribution of aripiprazole following
`administration is high (404 L or 4.9 L/kg), indicating extensive extravascular distribution.
`At therapeutic concentrations, aripiprazole and its major metabolite are greater than 99%
`bound to serum proteins, primarily to albumin. In healthy human volunteers administered
`0.5 to 30 mg/day aripiprazole for 14 days, there was dose-dependent D2 receptor
`occupancy indicating brain penetration of aripiprazole in humans.
`
`Metabolism and Elimination
`
`three biotransformation pathways:
`is metabolized primarily by
`Aripiprazole
`dehydrogenation, hydroxylation, and N-dealkylation. Based on in vitro studies, CYP3A4
`4 of 53
`
`Approved 1.0
`
`Item 2 current.pdf
`
`
`
`
`and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of
`aripiprazole, and N-dealkylation is catalyzed by CYP3A4. Aripiprazole is the
`predominant drug moiety in the systemic circulation. At steady state, dehydro-
`aripiprazole, the active metabolite, represents about 40% of aripiprazole AUC in plasma.
`
`Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6
`substrates and are classified as poor metabolizers (PM), whereas the rest are extensive
`metabolizers (EM). PMs have about an 80% increase in aripiprazole exposure and about
`a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about
`a 60% higher exposure to the total active moieties from a given dose of aripiprazole
`compared to EMs. Coadministration of ABILIFY with known inhibitors of CYP2D6, like
`quinidine in EMs, results in a 112% increase in aripiprazole plasma exposure, and dosing
`adjustment is needed (see PRECAUTIONS: Drug-Drug Interactions). The mean
`elimination half-lives are about 75 hours and 146 hours for aripiprazole in EMs and PMs,
`respectively. Aripiprazole does not inhibit or induce the CYP2D6 pathway.
`
`Following a single oral dose of [14C]-labeled aripiprazole, approximately 25%
`and 55% of the administered radioactivity was recovered in the urine and feces,
`respectively. Less than 1% of unchanged aripiprazole was excreted in the urine and
`approximately 18% of the oral dose was recovered unchanged in the feces.
`
`INTRAMUSCULAR ADMINISTRATION
`
`In two pharmacokinetic studies of aripiprazole injection administered intramuscularly to
`healthy subjects, the median times to the peak plasma concentrations were at 1 and 3
`hours. A 5-mg intramuscular injection of aripiprazole had an absolute bioavailability of
`100%. The geometric mean maximum concentration achieved after an intramuscular dose
`was on average 19% higher than the Cmax of the oral tablet. While the systemic exposure
`over 24 hours was generally similar between aripiprazole injection given intramuscularly
`and after oral tablet administration, the aripiprazole AUC in the first 2 hours after an
`intramuscular injection was 90% greater than the AUC after the same dose as a tablet. In
`stable patients with schizophrenia or schizoaffective disorder, the pharmacokinetics of
`aripiprazole after intramuscular administration were linear over a dose range of 1 to 45
`mg. Although the metabolism of aripiprazole injection was not systematically evaluated,
`the intramuscular route of administration would not be expected to alter the metabolic
`pathways.
`
`108
`109
`110
`111
`
`112
`113
`114
`115
`116
`117
`118
`119
`120
`121
`
`122
`123
`124
`125
`
`126
`
`127
`128
`129
`130
`131
`132
`133
`134
`135
`136
`137
`138
`139
`
`5 of 53
`
`Approved 1.0
`
`Item 2 current.pdf
`
`
`
`140
`
`141
`142
`143
`144
`
`145
`
`146
`147
`148
`149
`
`150
`
`151
`152
`153
`154
`155
`156
`
`157
`
`158
`159
`160
`161
`162
`163
`164
`165
`
`166
`
`167
`168
`
`
`Special Populations
`
`In general, no dosage adjustment for ABILIFY is required on the basis of a patient’s age,
`gender, race, smoking status, hepatic function, or renal function (see DOSAGE AND
`ADMINISTRATION: Dosage in Special Populations). The pharmacokinetics of
`aripiprazole in special populations are described below.
`
`Hepatic Impairment
`
`In a single-dose study (15 mg of aripiprazole) in subjects with varying degrees of liver
`cirrhosis (Child-Pugh Classes A, B, and C), the AUC of aripiprazole, compared to
`healthy subjects, increased 31% in mild HI, increased 8% in moderate HI, and decreased
`20% in severe HI. None of these differences would require dose adjustment.
`
`Renal Impairment
`
`In patients with severe renal impairment (creatinine clearance <30 mL/min), Cmax of
`aripiprazole (given in a single dose of 15 mg) and dehydro-aripiprazole increased by 36%
`and 53%, respectively, but AUC was 15% lower for aripiprazole and 7% higher for
`dehydro-aripiprazole. Renal excretion of both unchanged aripiprazole and dehydro-
`aripiprazole is less than 1% of the dose. No dosage adjustment is required in subjects
`with renal impairment.
`
`Elderly
`
`In formal single-dose pharmacokinetic studies (with aripiprazole given in a single dose of
`15 mg), aripiprazole clearance was 20% lower in elderly (≥65 years) subjects compared
`to younger adult subjects (18 to 64 years). There was no detectable age effect, however,
`in the population pharmacokinetic analysis in schizophrenia patients. Also, the
`pharmacokinetics of aripiprazole after multiple doses in elderly patients appeared similar
`to that observed in young, healthy subjects. No dosage adjustment is recommended for
`elderly patients (see Boxed WARNING, WARNINGS: Increased Mortality in Elderly
`Patients with Dementia-Related Psychosis, and PRECAUTIONS: Geriatric Use).
`
`Gender
`
`Cmax and AUC of aripiprazole and its active metabolite, dehydro-aripiprazole, are 30 to
`40% higher in women than in men, and correspondingly, the apparent oral clearance of
`6 of 53
`
`Approved 1.0
`
`Item 2 current.pdf
`
`
`
`
`aripiprazole is lower in women. These differences, however, are largely explained by
`differences in body weight (25%) between men and women. No dosage adjustment is
`recommended based on gender.
`
`Race
`
`Although no specific pharmacokinetic study was conducted to investigate the effects of
`race on the disposition of aripiprazole, population pharmacokinetic evaluation revealed
`no evidence of clinically significant race-related differences in the pharmacokinetics of
`aripiprazole. No dosage adjustment is recommended based on race.
`
`Smoking
`
`Based on studies utilizing human liver enzymes in vitro, aripiprazole is not a substrate for
`CYP1A2 and also does not undergo direct glucuronidation. Smoking should, therefore,
`not have an effect on the pharmacokinetics of aripiprazole. Consistent with these in vitro
`results, population pharmacokinetic evaluation did not
`reveal any significant
`pharmacokinetic differences between smokers and nonsmokers. No dosage adjustment is
`recommended based on smoking status.
`
`Drug-Drug Interactions
`
`169
`170
`171
`
`172
`
`173
`174
`175
`176
`
`177
`
`178
`179
`180
`181
`182
`183
`
`184
`
`185
`
`Potential for Other Drugs to Affect ABILIFY
`
`186
`187
`188
`189
`
`190
`191
`192
`193
`194
`
`Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8,
`CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct
`glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or
`inducers of these enzymes, or other factors, like smoking, is unlikely.
`
`Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents
`that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole
`clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6
`(eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause
`increased blood levels.
`
`7 of 53
`
`Approved 1.0
`
`Item 2 current.pdf
`
`
`
`
`Potential for ABILIFY to Affect Other Drugs
`
`Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with
`drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10- to 30-mg/day
`doses of aripiprazole had no significant effect on metabolism by CYP2D6
`(dextromethorphan), CYP2C9 (warfarin), CYP2C19
`(omeprazole, warfarin), and
`CYP3A4 (dextromethorphan) substrates. Additionally, aripiprazole and dehydro-
`aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro
`(see PRECAUTIONS: Drug-Drug Interactions).
`
`Aripiprazole had no clinically important interactions with the following drugs:
`
`Famotidine: Coadministration of aripiprazole (given in a single dose of 15 mg)
`with a 40-mg single dose of the H2 antagonist famotidine, a potent gastric acid blocker,
`decreased the solubility of aripiprazole and, hence, its rate of absorption, reducing by
`37% and 21% the Cmax of aripiprazole and dehydro-aripiprazole, respectively, and by
`13% and 15%, respectively, the extent of absorption (AUC). No dosage adjustment of
`aripiprazole is required when administered concomitantly with famotidine.
`
`Valproate: When valproate (500-1500 mg/day) and aripiprazole (30 mg/day)
`were coadministered at steady state, the Cmax and AUC of aripiprazole were decreased
`by 25%. No dosage adjustment of aripiprazole is required when administered
`concomitantly with valproate.
`
`Lithium: A pharmacokinetic interaction of aripiprazole with lithium is unlikely
`because lithium is not bound to plasma proteins, is not metabolized, and is almost entirely
`excreted unchanged in urine. Coadministration of therapeutic doses of lithium (1200-
`1800 mg/day) for 21 days with aripiprazole (30 mg/day) did not result in clinically
`significant changes in the pharmacokinetics of aripiprazole or its active metabolite,
`dehydro-aripiprazole (Cmax and AUC increased by less than 20%). No dosage
`adjustment of aripiprazole is required when administered concomitantly with lithium.
`
`Dextromethorphan: Aripiprazole at doses of 10 to 30 mg per day for 14 days had
`no effect on dextromethorphan’s O-dealkylation to its major metabolite, dextrorphan, a
`pathway known to be dependent on CYP2D6 activity. Aripiprazole also had no effect on
`dextromethorphan’s N-demethylation to its metabolite 3-methyoxymorphan, a pathway
`
`195
`
`196
`197
`198
`199
`200
`201
`202
`
`203
`
`204
`205
`206
`207
`208
`209
`
`210
`211
`212
`213
`
`214
`215
`216
`217
`218
`219
`220
`
`221
`222
`223
`224
`
`8 of 53
`
`Approved 1.0
`
`Item 2 current.pdf
`
`
`
`
`known to be dependent on CYP3A4 activity. No dosage adjustment of dextromethorphan
`is required when administered concomitantly with aripiprazole.
`
`Warfarin: Aripiprazole 10 mg per day for 14 days had no effect on the
`pharmacokinetics of R- and S-warfarin or on the pharmacodynamic end point of
`International Normalized Ratio, indicating the lack of a clinically relevant effect of
`aripiprazole on CYP2C9 and CYP2C19 metabolism or the binding of highly protein-
`bound warfarin. No dosage adjustment of warfarin is required when administered
`concomitantly with aripiprazole.
`
`Omeprazole: Aripiprazole 10 mg per day for 15 days had no effect on the
`pharmacokinetics of a single 20-mg dose of omeprazole, a CYP2C19 substrate, in healthy
`subjects. No dosage adjustment of omeprazole
`is required when administered
`concomitantly with aripiprazole.
`
`Lorazepam: Coadministration of lorazepam injection (2 mg) and aripiprazole
`injection (15 mg) to healthy subjects (n=40: 35 males and 5 females; ages 19-45 years
`old) did not result in clinically important changes in the pharmacokinetics of either drug.
`No dosage adjustment of aripiprazole is required when administered concomitantly with
`lorazepam. However, the intensity of sedation was greater with the combination as
`compared to that observed with aripiprazole alone and the orthostatic hypotension
`observed was greater with the combination as compared to that observed with lorazepam
`alone (see PRECAUTIONS: General).
`
`Clinical Studies
`
`225
`226
`
`227
`228
`229
`230
`231
`232
`
`233
`234
`235
`236
`
`237
`238
`239
`240
`241
`242
`243
`244
`
`245
`
`246
`
`Schizophrenia
`
`247
`248
`249
`250
`251
`252
`253
`
`254
`255
`
`The efficacy of ABILIFY (aripiprazole) in the treatment of schizophrenia was evaluated
`in five short-term (4- and 6-week), placebo-controlled trials of acutely relapsed inpatients
`who predominantly met DSM-III/IV criteria for schizophrenia. Four of the five trials
`were able to distinguish aripiprazole from placebo, but one study, the smallest, did not.
`Three of these studies also included an active control group consisting of either
`risperidone (one trial) or haloperidol (two trials), but they were not designed to allow for
`a comparison of ABILIFY and the active comparators.
`
`In the four positive trials for ABILIFY, four primary measures were used for
`assessing psychiatric signs and symptoms. The Positive and Negative Syndrome Scale
`9 of 53
`
`Approved 1.0
`
`Item 2 current.pdf
`
`
`
`
`(PANSS) is a multi-item inventory of general psychopathology used to evaluate the
`effects of drug treatment in schizophrenia. The PANSS positive subscale is a subset of
`items in the PANSS that rates seven positive symptoms of schizophrenia (delusions,
`conceptual
`disorganization,
`hallucinatory
`behavior,
`excitement,
`grandiosity,
`suspiciousness/persecution, and hostility). The PANSS negative subscale is a subset of
`items in the PANSS that rates seven negative symptoms of schizophrenia (blunted affect,
`emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract
`thinking, lack of spontaneity/flow of conversation, and stereotyped thinking). The
`Clinical Global Impression (CGI) assessment reflects the impression of a skilled
`observer, fully familiar with the manifestations of schizophrenia, about the overall
`clinical state of the patient.
`
`In a 4-week trial (n=414) comparing two fixed doses of ABILIFY (15 or 30
`mg/day) and haloperidol (10 mg/day) to placebo, both doses of ABILIFY were superior
`to placebo in the PANSS total score, PANSS positive subscale, and CGI-severity score.
`In addition, the 15-mg dose was superior to placebo in the PANSS negative subscale.
`
`In a 4-week trial (n=404) comparing two fixed doses of ABILIFY (20 or
`30 mg/day) and risperidone (6 mg/day) to placebo, both doses of ABILIFY were superior
`to placebo in the PANSS total score, PANSS positive subscale, PANSS negative
`subscale, and CGI-severity score.
`
`In a 6-week trial (n=420) comparing three fixed doses of ABILIFY (10, 15, or
`20 mg/day) to placebo, all three doses of ABILIFY were superior to placebo in the
`PANSS total score, PANSS positive subscale, and the PANSS negative subscale.
`
`In a 6-week trial (n=367) comparing three fixed doses of ABILIFY (2, 5, or 10
`mg/day) to placebo, the 10-mg dose of ABILIFY was superior to placebo in the PANSS
`total score, the primary outcome measure of the study. The 2-mg and 5-mg doses did not
`demonstrate superiority to placebo on the primary outcome measure.
`
`In a fifth study, a 4-week trial (n=103) comparing ABILIFY in a range of 5 to 30
`mg/day or haloperidol 5 to 20 mg/day to placebo, haloperidol was superior to placebo, in
`the Brief Psychiatric Rating Scale (BPRS), a multi-item inventory of general
`psychopathology traditionally used to evaluate the effects of drug treatment in psychosis,
`and in a responder analysis based on the CGI-severity score, the primary outcomes for
`
`256
`257
`258
`259
`260
`261
`262
`263
`264
`265
`266
`
`267
`268
`269
`270
`
`271
`272
`273
`274
`
`275
`276
`277
`
`278
`279
`280
`281
`
`282
`283
`284
`285
`286
`
`10 of 53
`
`Approved 1.0
`
`Item 2 current.pdf
`
`
`
`
`that trial. ABILIFY was only significantly different compared to placebo in a responder
`analysis based on the CGI-severity score.
`
`Thus, the efficacy of 10-mg, 15-mg, 20-mg, and 30-mg daily doses was
`established in two studies for each dose. Among these doses, there was no evidence that
`the higher dose groups offered any advantage over the lowest dose group of these studies.
`
`An examination of population subgroups did not reveal any clear evidence of
`differential responsiveness on the basis of age, gender, or race.
`
`A longer-term trial enrolled 310 inpatients or outpatients meeting DSM-IV
`criteria for schizophrenia who were, by history, symptomatically stable on other
`antipsychotic medications for periods of 3 months or longer. These patients were
`discontinued from their antipsychotic medications and randomized to ABILIFY 15 mg or
`placebo for up to 26 weeks of observation for relapse. Relapse during the double-blind
`phase was defined as CGI-Improvement score of ≥5 (minimally worse), scores ≥5
`(moderately severe) on the hostility or uncooperativeness items of the PANSS, or ≥20%
`increase in the PANSS total score. Patients receiving ABILIFY 15 mg experienced a
`significantly longer time to relapse over the subsequent 26 weeks compared to those
`receiving placebo.
`
`Bipolar Disorder
`
`The efficacy of ABILIFY in the treatment of acute manic episodes was established in two
`3-week, placebo-controlled trials in hospitalized patients who met the DSM-IV criteria
`for Bipolar I Disorder with manic or mixed episodes (in one trial, 21% of placebo and
`42% of ABILIFY-treated patients had data beyond two weeks). These trials included
`patients with or without psychotic features and with or without a rapid-cycling course.
`
`The primary instrument used for assessing manic symptoms was the Young
`Mania Rating Scale (Y-MRS), an 11-item clinician-rated scale traditionally used to assess
`the degree of manic symptomatology (irritability, disruptive/aggressive behavior, sleep,
`elevated mood, speech, increased activity, sexual interest, language/thought disorder,
`thought content, appearance, and insight) in a range from 0 (no manic features) to 60
`(maximum score). A key secondary instrument included the Clinical Global Impression -
`Bipolar (CGI-BP) scale.
`
`287
`288
`
`289
`290
`291
`
`292
`293
`
`294
`295
`296
`297
`298
`299
`300
`301
`302
`303
`
`304
`
`305
`306
`307
`308
`309
`
`310
`311
`312
`313
`314
`315
`316
`
`11 of 53
`
`Approved 1.0
`
`Item 2 current.pdf
`
`
`
`317
`318
`319
`320
`
`321
`322
`323
`324
`325
`326
`327
`328
`329
`330
`331
`332
`333
`334
`
`335
`336
`337
`338
`
`339
`
`340
`341
`342
`343
`344
`345
`346
`347
`348
`349
`
`
`
`In the two positive, 3-week, placebo-controlled trials (n=268; n=248) which
`evaluated ABILIFY 15 or 30 mg/day, once daily (with a starting dose of 30 mg/day),
`ABILIFY was superior to placebo in the reduction of Y-MRS total score and CGI-BP
`Severity of Illness score (mania).
`
`A trial was conducted in patients meeting DSM-IV criteria for Bipolar I Disorder
`with a recent manic or mixed episode who had been stabilized on open-label ABILIFY
`and who had maintained a clinical response for at least 6 weeks. The first phase of this
`trial was an open-label stabilization period in which inpatients and outpatients were
`clinically stabilized and then maintained on open-label ABILIFY (15 or 30 mg/day, with
`a starting dose of 30 mg/day) for at least 6 consecutive weeks. One hundred sixty-one
`outpatients were then randomized in a double-blind fashion, to either the same dose of
`ABILIFY they were on at the end of the stabilization and maintenance period or placebo
`and were then monitored for manic or depressive relapse. During the randomization
`phase, ABILIFY was superior to placebo on time to the number of combined affective
`relapses (manic plus depressive), the primary outcome measure for this study. The
`majority of these relapses were due to manic rather than depressive symptoms. There is
`insufficient data to know whether ABILIFY is effective in delaying the time to
`occurrence of depression in patients with Bipolar I Disorder.
`
`An examination of population subgroups did not reveal any clear evidence of
`differential responsiveness on the basis of age and gender; however, there were
`insufficient numbers of patients in each of the ethnic groups to adequately assess inter-
`group differences.
`
`Agitation Associated with Schizophrenia or Bipolar Mania
`
`The efficacy of intramuscular aripiprazole for injection for the treatment of agitation was
`established in three short-term (24-hour), placebo-controlled trials in agitated inpatients
`from two diagnostic groups: schizophrenia and Bipolar I Disorder (manic or mixed
`episodes, with or without psychotic features). Each of the trials included a single active
`comparator treatment arm of either haloperidol injection (schizophrenia studies) or
`lorazepam injection (bipolar mania study). Patients could receive up to three injections
`during the 24-hour treatment periods; however, patients could not receive the second
`injection until after the initial 2-hour period when the primary efficacy measure was
`assessed. Patients enrolled in the trials needed to be: (1) judged by the clinical
`investigators as clinically agitated and clinically appropriate candidates for treatment with
`12 of 53
`
`Approved 1.0
`
`Item 2 current.pdf
`
`
`
`
`intramuscular medication, and (2) exhibiting a level of agitation that met or exceeded a
`threshold score of ≥15 on the five items comprising the Positive and Negative Syndrome
`Scale (PANSS) Excited Component (ie, poor impulse control, tension, hostility,
`uncooperativeness, and excitement items) with at least two individual item scores ≥4
`using a 1-7 scoring system (1 = absent, 4 = moderate, 7 = extreme). In the studies, the
`mean baseline PANSS Excited Component score was 19, with scores ranging from 15 to
`34 (out of a maximum score of 35), thus suggesting predominantly moderate levels of
`agitation with some patients experiencing mild or severe levels of agitation. The primary
`efficacy measure used for assessing agitation signs and symptoms in these trials was the
`change from baseline in the PANSS Excited Component at 2 hours post-injection. A key
`secondary measure was the Clinical Global Impression of Improvement (CGI-I) scale.
`The results of the trials follow:
`
`(1) In a placebo-controlled trial in agitated inpatients predominantly meeting
`DSM-IV criteria for schizophrenia (n=350), four fixed aripiprazole injection doses of 1
`mg, 5.25 mg, 9.75 mg, and 15 mg were evaluated. At 2 hours post-injection, the 5.25-mg,
`9.75-mg, and 15-mg doses were statistically superior to placebo in the PANSS Excited
`Component and on the CGI-I scale.
`
`(2) In a second placebo-controlled trial in agitated inpatients predominantly
`meeting DSM-IV criteria for schizophrenia (n=445), one fixed aripiprazole injection dose
`of 9.75 mg was evaluated. At 2 hours post-injection, aripiprazole for injection was
`statistically superior to placebo in the PANSS Excited Component and on the CGI-I
`scale.
`
`(3) In a placebo-controlled trial in agitated inpatients meeting DSM-IV
`criteria for Bipolar I Disorder (manic or mixed) (n=291), two fixed aripiprazole
`injection doses of 9.75 mg and 15 mg were evaluated. At 2 hours post-injection,
`both doses were statistically superior to placebo in the PANSS Excited
`Component.
`
`Examination of population subsets (age, race, and gender) did not reveal any
`differential responsiveness on the basis of these subgroupings.
`
`350
`351
`352
`353
`354
`355
`356
`357
`358
`359
`360
`361
`
`362
`363
`364
`365
`366
`
`367
`368
`369
`370
`371
`
`372
`373
`374
`375
`376
`
`377
`378
`
`13 of 53
`
`Approved 1.0
`
`Item 2 current.pdf
`
`
`
`379
`
`380
`
`381
`382
`383
`
`384
`385
`386
`387
`388
`389
`390
`391
`
`392
`
`393
`394
`
`395
`396
`397
`398
`
`399
`400
`401
`402
`403
`404
`405
`406
`407
`408
`
`
`INDICATIONS AND USAGE
`
`Schizophrenia
`
`ABILIFY is indicated for the treatment of schizophrenia. The efficacy of ABILIFY in the
`treatment of schizophrenia was established in short-term (4- and 6-week) controlled trials
`of schizophrenic inpatients (see CLINICAL PHARMACOLOGY: Clinical Studies).
`
`The efficacy of ABILIFY in maintaining stability in patients with schizophrenia
`who had been symptomatically stable on other antipsychotic medications for periods of 3
`months or longer, were discontinued from those other medications, and were then
`administered ABILIFY 15 mg/day and observed for relapse during a period of up to 26
`(see CLINICAL
`weeks was demonstrated
`in
`a placebo-controlled
`trial
`PHARMACOLOGY: Clinical Studies). The physician who elects to use ABILIFY for
`extended periods should periodically re-evaluate the long-term usefulness of the drug for
`the individual patient (see DOSAGE AND ADMINISTRATION).
`
`Bipolar Disorder
`
`ABILIFY is indicated for the treatment of acute manic and mixed episodes associated
`with Bipolar Disorder.
`
`The efficacy of ABILIFY was established in two placebo-controlled trials (3
`week) of inpatients with DSM-IV criteria for Bipolar I Disorder who were experiencing
`an acute manic or mixed episode with or without psychotic features (see CLINICAL
`PHARMACOLOGY: Clinical Studies).
`
`The efficacy of ABILIFY in maintaining efficacy in patients with Bipolar I
`Disorder with a recent manic or mixed episode who had been stabilized and then
`maintained for at least 6 weeks, was demonstrated in a double-blind, placebo-controlled
`trial. Prior to entering the double-blind, randomization phase of this trial, patients were
`clinically stabilized and maintained their stability for 6 consecutive weeks on ABILIFY.
`Following this 6-week maintenance phase, patients were randomized to either placebo or
`ABILIFY and monitored for relapse (see CLINICAL PHARMACOLOGY: Clinical
`Studies). Physicians who elect to use ABILIFY for extended periods, that is,